Russian Heart Failure Journal 2012year Chronic kidney disease: influence on frequency, duration and costs of hospitalizations in patients with chronic heart failure


To access this material please log in or register

Register Authorize
2012/№1

Chronic kidney disease: influence on frequency, duration and costs of hospitalizations in patients with chronic heart failure

Makeeva E. R.

Keywords: hospitalisation, chronic kidney disease, CHF

DOI: 10.18087/rhfj.2012.1.1639

Relevance. Optimization of CHF treatment by the reduction of number of repeated hospitalizations is necessary both from medical and social points of view. Objective. Study of the influence of chronic kidney disease (CKD) on frequency and duration of hospitalizations, as well as on direct medical costs of CHF patients’ hospitalization. Materials and methods. Nonrandomized open-label prospective study in the parallel groups included 308 patients with CHF. Two CHF patients groups were compared: with CKD (GFR <60 ml / min / 1.73 m2) and without CKD (GFR ≥60 ml / min / 1.73 m2). Cost analysis of hospitalizations due to all reasons and concerning CVD exacerbations depending on occurrence of CKD was performed. Results. CKD was diagnosed in 108 patients with (35 %). At occurrence of CKD, mean annual number of hospitalizations due to all reasons per CHF patient was 1.2±0.2 versus 0.9±0.1 per CHF patient without CKD (p=0.001); due to CVD exacerbations at occurrence of CKD – 1.2±0.2 versus 0.9±0.1 without CKD (p=0.001). Presence of CKD increased costs of CHF patients’ hospitalization by 26 %. Conclusion. Presence of CKD in CHF patients increases rate of hospitalizations due to all reasons and due to CVD exacerbation, duration and costs, which must be taken into account at planning of the treatment of this group of patients.
  1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др Истинная распространенность ХСН в Европейской части Российской Федерации. Журнал Сердечная недостаточность. 2011;12 (2):63–68.
  2. Mulvey GK, Wang Y, Lin Z et al. Mortality and readmission for patients with heart failure among U. S. News & World Report’s top heart hospitals. Circ Cardiovasc Qual Outcomes. 2009;2 (6):558–565.
  3. Карпов Ю. А., Мареев В. Ю., Чазова И. Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Журнал Сердечная Недостаточность. 2003;4 (5):261–265.
  4. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113 (5):671–678.
  5. National Kidney Foundation. K / DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39 (Suppl 1):S17‑S31.
  6. Brosius FC 3rd, Hostetter TH, Kelepouris E et al. Detection of chro­nic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114 (10):1083–1087.
  7. Klein L, Massie BM, Leimberger JD et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1 (1):25–33.
  8. Ghali JK, Wikstrand J, Van Veldhuisen DJ et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR / XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail. 2009;15 (4):310–318.
  9. Dimopoulos K, Diller GP, Koltsida E et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart di­sease. Circulation. 2008;117 (18):2320–2328.
  10. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S et al. Chronic Kidney Disease as an Independent Risk for Long-Term Adverse Outcomes in Patients Hospitalized With Heart Failure in Japan. Circ J. 2009;73 (8):1442–1447.
  11. Damman K, Voors AA, Navis G et al. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis. 2011;54 (2):144–153.
  12. Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22 (2):208–215.
  13. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  14. Sandhu A, Soman S, Hudson M, Besarab A. Managing anemia in patients with chronic heart failure: what do we know? Vasc Health Risk Manag. 2010;6:237–252.
  15. Caramelo C, Justo S, Gil P. Anemia in heart failure: pathophysio­logy, pathogenesis, treatment, and incognitae. Rev Esp Cardiol. 2007;60 (8):848–860.
  16. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55 (4):726–741.
  17. Go AS, Yang J, Ackerson LM et al. Hemoglobin level, chronic kidney di­sease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113 (23):2713–2723.
  18. Shiba N, Matsuki M, Takahashi J et al. Prognostic importance of chro­nic kidney disease in Japanese patients with chronic heart failure. Circ J. 2008;72 (2):173–178.
  19. Deo R, Fyr CL, Fried LF et al. Kidney dysfunction and fatal cardiovascular disease – an association independent of atherosclerotic events: results from the Health, Aging, and Body Composition (Health ABC) study. Am Heart J. 2008;155 (1):62–68.
  20. O’Meara E, Clayton T, McEntegart MB et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart fai­lure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115 (24):3111–3120.
  21. Серов В. А., Шутов А. М., Сучков В. Н. и др. Влияние хронической болезни почек на прогноз больных хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2009;10 (4):202–204.
  22. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158 (4):629–636.
  23. Шутов А. М., Серов В. А., Гердт А. М. и др. Хроническая болезнь почек предрасполагает к фибрилляции предсердий у больных с хронической сердечной недостаточностью. Нефрология. 2008;4:49–53.
  24. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remo­deling during atrial fibrillation. Cardiovasc Res. 2002;54 (2):230–234.
  25. Amann K, Ritz E. Cardiovascular abnormalities in ageing and in uraemia – only analogy or shared pathomechanisms? Nephrol Dial Transplant. 1998;13 (Suppl 7):6–11.
  26. Everett TH 4th, Li H, Mangrum JM et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation. 2000;102 (12):1454–1460.
  27. Camm AJ, Lip GYH, Schotten U et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (developed with the special contribution of the European Heart Rhythm Association, endorsed by the European Association for Cardio-Thoracic Surgery). Eur Heart J. 2010;31 (19):2369–2429.
  28. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology (Carlton). 2010;15 (Suppl 2):3–9.
  29. Kubacki M, Carter C, Herrera ADL et al. Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population. American health & Drug benefits. 2009;2 (7):283–290.
  30. Электронный ресурс, 2010. Доступно на: http://www.perepis-2010.ru / results_of_the_census / results-inform. php.
Makeeva E.R. Chronic kidney disease: influence on frequency, duration and costs of hospitalizations in patients with chronic heart failure. Russian Heart Failure Journal. 2012;13(1):32-35

To access this material please log in or register

Register Authorize
Ru En